Pfizer Inc. (PFE) Just Had This Drug Approved By The European Commission
Pfizer Inc. had some exciting news this week when the pharmaceutical giant reported that the European Commission (EC) has approved Nimenrix™ for infants as early as six weeks of age.
This is huge because it makes Nimenrix the only MenACWY conjugate vaccine in the European Union which can be used at the six week time period.
Disclaimer: We have no position in Pfizer Inc. (NYSE: PFE) and have not been compensated for this article.